BioCentury
ARTICLE | Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

July 28, 2020 12:16 AM UTC

The earliest clinical efficacy data for TCR2’s mesothelin-targeted TRuC T cell therapy hint that the engineered TCR T cells may work in solid tumors, where CAR T cells have yet to shine.

Shares of TCR Therapeutics Inc. (NASDAQ:TCRR) gained 25% on Monday to $16.39 after the company announced the first five patients treated in the Phase I part of a Phase I/II trial evaluating TC-210 all experienced regression of their mesothelin-expressing solid tumors. ...

BCIQ Company Profiles

TCR2 Therapeutics Inc.

BCIQ Target Profiles

Mesothelin (MSLN)